intensive insulin therapy to maintain normoglycemia
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Critical Illness
Conditions
Critical Illness
Trial Timeline
Mar 1, 2002 → Jun 1, 2005
NCT ID
NCT00115479About intensive insulin therapy to maintain normoglycemia
intensive insulin therapy to maintain normoglycemia is a phase 2 stage product being developed by Novo Nordisk for Critical Illness. The current trial status is completed. This product is registered under clinical trial identifier NCT00115479. Target conditions include Critical Illness.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00115479 | Phase 2 | Completed |
Competing Products
13 competing products in Critical Illness
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin | Merck | Approved | 85 |
| Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose | Merck | Phase 1 | 33 |
| Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months. | Amgen | Approved | 84 |
| Midazolam + Dexmedetomidine | Pfizer | Pre-clinical | 22 |
| Apixaban + ASA + Clopidogrel 75mg | Pfizer | Phase 3 | 76 |
| Colchicine (Colcrys®) + placebo + allopurinol | Regeneron Pharmaceuticals | Approved | 84 |
| Rilonacept 80 mg + Rilonacept 160 mg | Regeneron Pharmaceuticals | Phase 3 | 76 |
| treprostinil dienthanolmine sustained release + Placebo | United Therapeutics | Phase 2 | 49 |
| Remodulin® (treprostinil sodium) Injection | United Therapeutics | Phase 3 | 74 |
| Olimel (5.7%E / N9E) | Baxter | Phase 3 | 74 |
| Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Baxter | Approved | 82 |
| RJX + Placebo | ICON plc. | Phase 1 | 30 |
| Ixmyelocel-T | Vericel | Phase 3 | 72 |